Knowledge and quality of life in cancer patients receiving immunotherapy for the first time. A cross-sectional study about being informed.

Abstract

Purpose: Patients receiving immunotherapy need to have a good understanding of how immunology works and which toxicities they can expect. This study aimed to assess patients' knowledge on their immunotherapies and their quality of life before and after receiving immunotherapy for the first time in a cancer centre.

Methods: From July 2018 to September 2020, all patients treated at the cancer centre receiving first-time immunotherapy were invited to participate in a cross-sectional descriptive study. Non-probabilistic sampling was used to recruit 138 patients, who answered a basal ad hoc questionnaire with ten items assessing their previous knowledge on immunotherapy. Clinical variables were collected from records and by advanced clinical specialist nurses' interviews, and quality of life was evaluated at 2 points (basal and 8 weeks of treatment), using the European Organisation for Research and Treatment of Cancer-Quality of Life C30 scale.

Results: Our descriptive analysis of 138 participants with solid tumours showed that 98.5% knew they were receiving immunotherapy. Regarding complications, 89.8% reported that skin reactions were a major problem. The pre-post comparison of overall health status/health-related quality of life did not show significant changes with treatment.

Conclusion: Our participants were comprised primarily of men with lung cancer, receiving care at a multidisciplinary outpatient unit where they got information from their oncologist and were later assessed by clinical nurse specialists. Almost all considered themselves to be well informed, despite receiving the immunotherapy for the first time. Specific expertise, skills and abilities of the health team, oncologist and nurses providing the care that patients receiving immunotherapy needs are essential.